AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31692308 — intervention group
Group type: COMPARATOR
Intervention: Ortho HCV 3.0 ELISA and Cobas Taqman HCV RNA assays
Number of subjects: 1408
Study 29492753 — intervention group
Group type: EXPERIMENTAL
Intervention: App+Reminder (weekly reminders to use app)
Number of subjects: 44
Study 29492753 — intervention group
Group type: COMPARATOR
Intervention: App (no reminders)
Number of subjects: 44
Study 25902387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (IVA) preoperatively
Number of subjects: 150
Study 25902387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (IVA) within 30 minutes of surgery
Number of subjects: 150
Study 25902387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVA)
Number of subjects: 150
Study 24713595 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminar airflow system
Number of subjects: 63
Study 24713595 — intervention group
Group type: COMPARATOR
Intervention: Displacement ventilation system
Number of subjects: 63
Study 22889730 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (15 g protein at breakfast and lunch)
Number of subjects: 65
Study 22889730 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 65
Study 22889730 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 65
Study 19469426 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape training group
Number of subjects: 0
Study 19469426 — intervention group
Group type: COMPARATOR
Intervention: Lecture training group
Number of subjects: 0
Study 17766770 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-focused psychoeducation
Number of subjects: 60
Study 15244109 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressen (twice daily for 30 days)
Number of subjects: 40
Study 15244109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 11784735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral lesions of primary auditory cortex and surrounding areas
Number of subjects: 13
Study 11784735 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral lesions of auditory cortex, auditory midbrain, or dorsolateral frontal cortex
Number of subjects: 13
Study 11784735 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 13
Study 11784735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral auditory cortex lesions
Number of subjects: 13
Study 9698966 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30
Study 9698966 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 10172084 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/kg r‐hu EPO
Number of subjects: 62
Study 10172084 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/kg r‐hu EPO
Number of subjects: 62
Study 10172084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2532102 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 37
Study 2532102 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin injection treatment
Number of subjects: 37
Study 2532102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (CSII and injections)
Number of subjects: 37
Study 59150 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine sulphate 320 mg
Number of subjects: 9
Study 59150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31221872 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive (a chance to get shopping points) for increasing daily steps
Number of subjects: 0
Study 31221872 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 27269410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferrous sucrose (up to three calculated replacement doses)
Number of subjects: 352
Study 27269410 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate (150 mg twice daily for six weeks)
Number of subjects: 352
Study 25831420 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus (9vHPV) vaccine administered concomitantly with REPEVAX (diphtheria, tetanus, pertussis, and poliomyelitis vaccines)
Number of subjects: 1054
Study 25831420 — intervention group
Group type: EXPERIMENTAL
Intervention: REPEVAX (diphtheria, tetanus, pertussis, and poliomyelitis vaccines)
Number of subjects: 1054
Study 25831420 — intervention group
Group type: COMPARATOR
Intervention: Nonconcomitant vaccination group (REPEVAX administered at month 1)
Number of subjects: 1054
Study 22858889 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery room temperature set at 25.1±0.6 °C
Number of subjects: 91
Study 22858889 — intervention group
Group type: COMPARATOR
Intervention: Delivery room temperature set at 22.5±0.6 °C
Number of subjects: 91
Study 23724225 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg inhaled budesonide
Number of subjects: 37
Study 23724225 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg prednisolone orally daily
Number of subjects: 37
Study 23724225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for prednisolone trial)
Number of subjects: 37
Study 23724225 — intervention group
Group type: COMPARATOR
Intervention: No treatment (for budesonide trial)
Number of subjects: 37
Study 23724225 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol and high-density lipoprotein
Number of subjects: 37
Study 19447001 — intervention group
Group type: EXPERIMENTAL
Intervention: Genesis II HF insert
Number of subjects: 100
Study 19447001 — intervention group
Group type: COMPARATOR
Intervention: Genesis II PS insert
Number of subjects: 100
Study 17055767 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice physiotherapy
Number of subjects: 173
Study 17055767 — intervention group
Group type: COMPARATOR
Intervention: No physiotherapy (Control)
Number of subjects: 173
Study 15119877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed prosthesis (n = 11)
Number of subjects: 17
Study 15119877 — intervention group
Group type: COMPARATOR
Intervention: Overdenture (n = 6)
Number of subjects: 17
Study 11110928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodynamic thrombectomy system
Number of subjects: 120
Study 11110928 — intervention group
Group type: COMPARATOR
Intervention: Pulse-spray thrombolysis
Number of subjects: 120
Study 11110928 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus treatment time for thrombectomy
Number of subjects: 120
Study 11110928 — intervention group
Group type: COMPARATOR
Intervention: Thrombus treatment time for thrombolysis
Number of subjects: 120
Study 8958538 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 107
Study 8958538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1%
Number of subjects: 107
Study 8958538 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 107
Study 8958538 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 107
Study 1389191 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane in 60% N2O
Number of subjects: 34
Study 1389191 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane in 60% N2O
Number of subjects: 34
Study 2581324 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam 200 mg once daily
Number of subjects: 309
Study 2581324 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg 3 times a day
Number of subjects: 309
Study 30637748 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin (PRF) membrane
Number of subjects: 20
Study 30637748 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane (CM) incorporated with recombinant human PDGF‐BB (rhPDGF‐BB)
Number of subjects: 20
Study 30637748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PRF membrane and CM incorporated with rhPDGF‐BB
Number of subjects: 20
Study 27612525 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone 32 mg)
Number of subjects: 60
Study 27612525 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (methylprednisolone 32 mg and meloxicam 15 mg)
Number of subjects: 60
Study 27612525 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (meloxicam 15 mg)
Number of subjects: 60
Study 25057930 — intervention group
Group type: EXPERIMENTAL
Intervention: Echogenic needles
Number of subjects: 0
Study 25057930 — intervention group
Group type: COMPARATOR
Intervention: Conventional needles
Number of subjects: 0
Study 22717018 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 133
Study 22717018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 21696732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose fosfomycin trometamol
Number of subjects: 90
Study 21696732 — intervention group
Group type: COMPARATOR
Intervention: 5-day course of amoxicillin clavulanate
Number of subjects: 90
Study 21696732 — intervention group
Group type: COMPARATOR
Intervention: 5-day course of cefuroxime axetil
Number of subjects: 90
Study 18224344 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors for mild IgA nephropathy
Number of subjects: 500
Study 18224344 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids for severe IgA nephropathy
Number of subjects: 500
Study 18224344 — intervention group
Group type: EXPERIMENTAL
Intervention: Period 1990-2004
Number of subjects: 500
Study 18224344 — intervention group
Group type: COMPARATOR
Intervention: Period 1976-1989
Number of subjects: 500
Study 17194243 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr) supplementation at a dose of 0.3 g.kg(‐1) for the initial 7 days and 0.03 g.kg(‐1) for subsequent 9 weeks
Number of subjects: 26
Study 17194243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl) at a dose of 0.3 g.kg(‐1) for the initial 7 days and 0.03 g.kg(‐1) for subsequent 9 weeks
Number of subjects: 26
Study 14989126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 0
Study 14989126 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality treatment including IORT
Number of subjects: 0
Study 14989126 — intervention group
Group type: COMPARATOR
Intervention: Multimodality treatment without IORT
Number of subjects: 0
Study 10505694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan membrane (CU)
Number of subjects: 38
Study 10505694 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate membrane (PMMA)
Number of subjects: 38
Study 10505694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondialyzed uremic patients (UR)
Number of subjects: 38
Study 10505694 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 38
Study 8756734 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostilbegyt treatment (50 mg daily for 240 days)
Number of subjects: 57
Study 8756734 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG stimulation (6000 units of Biogonadyl through 2 days)
Number of subjects: 57
Study 1818002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (50 mcg/Kg over 5 min)
Number of subjects: 14
Study 1818002 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (5 mg over 5 min)
Number of subjects: 14
Study 6978143 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy opiate premedication
Number of subjects: 2
Study 6978143 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 2
Study 6978143 — intervention group
Group type: COMPARATOR
Intervention: Control (no premedication)
Number of subjects: 2
Study 31902653 — intervention group
Group type: COMPARATOR
Intervention: TLC + placebo
Number of subjects: 53
Study 31902653 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC + A/A
Number of subjects: 53
Study 31498922 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact exercise (EL)
Number of subjects: 42
Study 31498922 — intervention group
Group type: COMPARATOR
Intervention: Control leg (CL)
Number of subjects: 42
Study 25951117 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-professional training for physicians and nurses
Number of subjects: 0
Study 25951117 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained unit teams)
Number of subjects: 0
Study 27262086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2g daily)
Number of subjects: 57
Study 27262086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 25052710 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with epilepsy (CWE)
Number of subjects: 112
Study 25052710 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group (CWE and controls)
Number of subjects: 112
Study 25052710 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 112
Study 22807594 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stage intervention including educating staff, educating patients, and auditing surgeon practices (2005-2011)
Number of subjects: 0
Study 22807594 — intervention group
Group type: COMPARATOR
Intervention: Before intervention (2001-2004)
Number of subjects: 0
Study 22807594 — intervention group
Group type: EXPERIMENTAL
Intervention: After intervention (2005-2011)
Number of subjects: 0
Study 22807594 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall caesarean section rate
Number of subjects: 0
Study 22807594 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated pregnancies post-2004
Number of subjects: 0
Study 22807594 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean delivery rate
Number of subjects: 0
Study 19188900 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (biweekly sessions of 2 hours, energy expenditure of 2500 kJ/hour)
Number of subjects: 34
Study 19188900 — intervention group
Group type: COMPARATOR
Intervention: Non-specific oral advice to increase physical activity
Number of subjects: 34
Study 17665244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration glucose intravenously during 24 hours before the operation
Number of subjects: 57
Study 15799006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebervital (formulation A)
Number of subjects: 24
Study 15799006 — intervention group
Group type: COMPARATOR
Intervention: Neupogen (formulation B)
Number of subjects: 24
Study 12002769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus granulocyte colony-stimulating factor
Number of subjects: 16
Study 12002769 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 12002769 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior chemotherapy courses
Number of subjects: 16
Study 12002769 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease status or mobilizing regimen dose
Number of subjects: 16
Study 9578999 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool food service intervention program (reducing total fat to <30% of calories and saturated fat to <10% of calories)
Number of subjects: 0
Study 9578999 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive preschool health education curriculum focused on nutrition
Number of subjects: 0
Study 9578999 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cholesterol evaluation (semiannual)
Number of subjects: 0
Study 9578999 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth and body fatness assessment
Number of subjects: 0
Study 10201454 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided celiac block
Number of subjects: 22
Study 10201454 — intervention group
Group type: COMPARATOR
Intervention: CT-guided celiac block
Number of subjects: 22
Study 1992862 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 306
Study 1992862 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 306
Study 1992862 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 306
Study 6136432 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (10 mg)/droperidol (2.5 mg)/atropine (0.3 mg)
Number of subjects: 299
Study 6136432 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine (100 mg)/droperidol (2.5 mg)/atropine (0.3 mg)
Number of subjects: 299
Study 6136432 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine (100 mg)/droperidol (2.5 mg)
Number of subjects: 299
Study 31727024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + 12-weekly ipilimumab
Number of subjects: 189
Study 31727024 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab + 3-weekly ipilimumab
Number of subjects: 189
Study 31727024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab
Number of subjects: 189
Study 28935775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia (assessed using computed tomography scans)
Number of subjects: 237
Study 28935775 — intervention group
Group type: COMPARATOR
Intervention: No sarcopenia
Number of subjects: 237
Study 25934864 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)‐epicatechin (100 mg/d)
Number of subjects: 37
Study 25934864 — intervention group
Group type: EXPERIMENTAL
Intervention: quercetin‐3‐glucoside (160 mg/d)
Number of subjects: 37
Study 25934864 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 23515277 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited Naughton protocol treadmill exercise tests in HF with reduced EF
Number of subjects: 13
Study 23515277 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited Naughton protocol treadmill exercise tests in HF with preserved EF
Number of subjects: 13
Study 23515277 — intervention group
Group type: COMPARATOR
Intervention: Activities of daily living
Number of subjects: 13
Study 21195961 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed saline solution (37.5°C)
Number of subjects: 64
Study 21195961 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature saline solution
Number of subjects: 64
Study 18844082 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg soy isoflavone and 440 mg Ca and 100 IU VD supplement/d (n = 26)
Number of subjects: 93
Study 18844082 — intervention group
Group type: EXPERIMENTAL
Intervention: 440 mg Ca and 100 IU VD supplement/d (n = 26)
Number of subjects: 93
Study 18844082 — intervention group
Group type: COMPARATOR
Intervention: Observation group (T < -1.5)
Number of subjects: 93
Study 18844082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with Px haplotype
Number of subjects: 93
Study 18844082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects without Px haplotype
Number of subjects: 93
Study 18844082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Ca group and Ca + soy isoflavone group
Number of subjects: 93
Study 16580392 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) therapy for 3 months
Number of subjects: 30
Study 16580392 — intervention group
Group type: COMPARATOR
Intervention: Control group (fertile controls)
Number of subjects: 30
Study 16580392 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) therapy
Number of subjects: 30
Study 15486831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine, 300 mg per day for 7 days (n=18)
Number of subjects: 80
Study 15486831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine, 600 mg per day for 3 days (n=19)
Number of subjects: 80
Study 15486831 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine, 600 mg as a single dose (n=18)
Number of subjects: 80
Study 15486831 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (n=13)
Number of subjects: 80
Study 15486831 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine base, 15 mg per day for 14 days (n=12)
Number of subjects: 80
Study 11057986 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation
Number of subjects: 188
Study 11057986 — intervention group
Group type: COMPARATOR
Intervention: Hospital rehabilitation
Number of subjects: 188
Study 8773636 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH 1-34
Number of subjects: 10
Study 8773636 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol and calcium
Number of subjects: 10
Study 1734637 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 to 100 mg)
Number of subjects: 14
Study 1734637 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) (10 mg)
Number of subjects: 14
Study 1734637 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 to 100 mg) + Isosorbide dinitrate (ISDN) (10 mg)
Number of subjects: 14
Study 6469080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion (0.15 micrograms/kg/h)
Number of subjects: 10
Study 6469080 — intervention group
Group type: COMPARATOR
Intervention: Proglumide infusion (placebo control)
Number of subjects: 10
Study 31517700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Reality (MR) cognitive training system, 30 minutes of training 3 times a week for 6 weeks
Number of subjects: 21
Study 31517700 — intervention group
Group type: COMPARATOR
Intervention: Conventional computer-assisted cognitive training system, 30 minutes of training 3 times a week for 6 weeks
Number of subjects: 21
Study 30219477 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized tongxie formula
Number of subjects: 0
Study 30219477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30219477 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium
Number of subjects: 0
Study 27139058 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided self-help intervention (cognitive-behavioral and problem-solving therapy supported by an online trainer; n=202)
Number of subjects: 406
Study 27139058 — intervention group
Group type: COMPARATOR
Intervention: Web-based psychoeducation program (n=204)
Number of subjects: 406
Study 24476003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube placement (Group A)
Number of subjects: 145
Study 24476003 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube placement (Group B)
Number of subjects: 145
Study 22786596 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management therapy for MS (SMT‐MS)
Number of subjects: 121
Study 22786596 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 121